Back to Search
Start Over
[Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation]
- Source :
- Ugeskrift for laeger. 171(4)
- Publication Year :
- 2009
-
Abstract
- In haematological malignancies, molecular markers like fusion DNA from balanced translocations, point mutations, or over-expressed genes can now be used not only for diagnosis, but also for determination of the minimal residual disease (MRD) after cytoreduction with a sensitivity by far exceeding that of previous methodologies. The sensitivity of quantitative polymerase chain reaction typically reaches a validated identification of 1 malignant cell in 100,000.
Details
- ISSN :
- 16036824
- Volume :
- 171
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Ugeskrift for laeger
- Accession number :
- edsair.pmid..........163dc29729a70203904234a2c2433aa2